About these reports
Using data derived from Beacon Bispecific, The 2022 Bispecific Landscape Review series encompasses four reports that provide valuable insight to the 2022 bispecific landscape.
You will be given a complete overview of the existing landscape (as of the 24th January 2023), an in-depth analysis of what happened in 2022 from a drug and trial perspective, a look at what the future might bring, and a full list of all notable regulatory announcements.
This four part series consists of:
- The Drug Landscape – a thorough analysis of the bispecific drug landscape over the years, covering both oncology and non-oncology indications.
- The Trial Landscape – an analytical exploration of the bispecific trial landscape over the years.
- The Future of Bispecific Therapies – based on the current clinical and preclinical landscape.
- 2022 Regulatory Announcements – including collaborations, mergers and acquisitions, orphan drug designations and more.
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
Speak with our team
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated and leveraged on Beacon.
Beacon Bispecific
How the most complete bispecific database can help you
What we cover
This database solution is manually curated by sector-specific scientists and includes clinical trial and drug records for preclinical, active, approved, and discontinued antibody-based drugs that are designed to bind to two or more target antigens. We also cover:
- Whole Antibodies
- Antibody Fragments
- Augmented Antibodies
- Bispecific Fusion Proteins
How Beacon Bispecific works
Search the clinical trial and drug landscape by multiple targets, scaffold and over 80 different bispecific formats, instantaneously and/or extract the data points you need to conduct more complex analysis.
